Hemostatic Endothelial Dysfunction in Patients With Peripheral Artery Disease

Endothelial Dysfunction Clinical Trial

Official title: The Role of Hemostatic Markers of Endothelial Dysfunction in the Development of Disease Progression, Thrombotic Complications and Restenosis in Patients With Atherosclerotic Peripheral Artery Disease

Status Completed

Clinical Trial Summary

The study is aimed at evaluating the role of the activity of the key hemostatic parameters of endothelial dysfunction (nitric oxide II (NO) metabolites, plasmin activator inhibitor-1 (PAI-1), von Willebrand factor (vWF), coagulation factor VIII (FVIII), soluble endothelial protein C receptors (sEPCR)) in the development of disease progression, thrombotic complications and restenosis in subjects with atherosclerotic peripheral artery disease.

Clinical Trial Description

The study will involve patients with atherosclerotic peripheral artery disease (Rutherford category 3-5). The subjects are to be divided into three groups:

Group A: patients who undergo bypass surgery with a synthetic graft on aorto-iliac or femoro-popliteal segment; Group B: patients who undergo endovascular balloon angioplasty and stenting on aorto-iliac or femoro-popliteal segment; Group C: patients who undergo standard of care conservative treatment.

Decisions on revascularization or conservative treatment alone is to be made by a team of vascular specialists in accordance with the severity of the disease, previous treatment, anatomy, possible need for repeat procedures in the future, and patient's preferences. ;

Related Conditions & MeSH terms

• Endothelial Dysfunction
• Graft Occlusion, Vascular
• Peripheral Arterial Disease
• Peripheral Artery Disease
• Restenosis of Peripheral Vascular Stent
• Restenosis, Vascular Graft

• NCT number: NCT04391374
• Study type: Observational
• Source: Ryazan State Medical University
• Status: Completed
• Start date: January 2017
• Completion date: March 23, 2023